Chemotherapy for pulmonary tuberculosis. A short-course regimen and its rationale.
After years of declining incidence, pulmonary tuberculosis is increasing, owing in part to the influx of Asian refugees. An understanding of the tubercle bacillus and a knowledge of chemotherapy enable the physician to give adequate treatment. Short-course chemotherapy has been found to be 99% effective in clinical trials, leading the American Thoracic Society to recommend use of this mode of treatment.
D004359:Drug Therapy, Combination; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use*; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*; D012306:Risk; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000517:prevention & control*; D014481:United States
D007538:Isoniazid; D012293:Rifampin